A5067953805- Hepatitis C virus research
- Liver Disease Diagnosis and Treatment
- Hepatitis B Virus Studies
- Liver Disease and Transplantation
- Systemic Lupus Erythematosus Research
- Liver Diseases and Immunity
- Organ Transplantation Techniques and Outcomes
- Hepatitis Viruses Studies and Epidemiology
- Monoclonal and Polyclonal Antibodies Research
- Hepatocellular Carcinoma Treatment and Prognosis
- Renal Transplantation Outcomes and Treatments
- Legal Education and Practice Innovations
- Glycosylation and Glycoproteins Research
- Protease and Inhibitor Mechanisms
- Mechanical Circulatory Support Devices
- Viral gastroenteritis research and epidemiology
- Transplantation: Methods and Outcomes
- Cell Adhesion Molecules Research
- Immune Cell Function and Interaction
- HIV/AIDS drug development and treatment
- Chronic Lymphocytic Leukemia Research
- Glioma Diagnosis and Treatment
- Legal principles and applications
- Artificial Intelligence in Law
- Cholangiocarcinoma and Gallbladder Cancer Studies
University of Leeds
2022
University of Minnesota, Duluth
1979-2020
Bridge University
2020
Institute for Diabetes Discovery
2019
Baylor University Medical Center
2005-2014
University of Utah
2014
Baylor Scott & White All Saints Medical Center
2013
Flinders University
2004-2011
Baylor Scott & White Health
2011
Charles Darwin University
2010
This guideline has been approved by the American Association for Study of Liver Diseases and College Gastroenterology represents position both associations. These recommendations provide a data-supported approach to management patients with varices variceal hemorrhage. They are based on following: (1) formal review analysis recently published world literature topic (Medline search); (2) several consensus conferences among experts; (3) Physicians' Manual Assessing Health Practices Designing...
Chronic hepatitis C (non-A, non-B hepatitis) is a common and often progressive viral liver disease. To assess the efficacy of therapy with antiviral agent interferon alfa, we randomly assigned 166 patients chronic to treatment either 3 million or 1 units recombinant alfa three times weekly for 24 weeks, no treatment. The probability normalization near serum alanine aminotransferase levels after six months was 46 percent in treated (P<0.001) 28 those (P<0.02), but only 8 untreated patients....
Interferon alfa is the only effective treatment for patients with chronic hepatitis C. Forty percent of have an initial response to this therapy, but most subsequently relapse. We compared effect interferon alone that plus oral ribavirin relapses
The prevalence of chronic hepatitis C (CH-C) remains high and the complications infection are common. Our goal was to project future CH-C its complications.We developed a multicohort natural history model overcome limitations previous models for predicting disease outcomes benefits therapy.Prevalence peaked in 2001 at 3.6 million. Fibrosis progression inversely related age infection, so cirrhosis were most common after 60 years, regardless when occurred. proportion with is projected reach...
Interferon–based regimens for the treatment of chronic hepatitis C have become increasingly effective and are able to eradicate virus in more than one half cases. Early identification patients who will not respond is desirable because might be stopped, thereby avoiding expense inconvenience unnecessary therapy. We examined accuracy different degrees viral inhibition during early weeks (early virologic response [EVR]) with pegylated interferon alfa–2b ribavirin (PEG/R) identifying would The...
Chronic hepatitis C virus (HCV) infection is common and often results in slowly progressive liver disease. Although acute now uncommon, most patients with have developed chronic hepatitis, and, therefore, the pool of infected large. We used a modification previously described natural history model for HCV to project number cases infection, cirrhosis, failure over next 40 years. The estimated prevalence United States was 3.07 × 106 1993 (compared an adjusted National Health Nutrition...
Hepatitis C is a common cause of chronic liver disease that may progress to cirrhosis. We conducted multicenter double-blind placebo-controlled trial ribavirin 600 mg given orally twice daily for 36 weeks with follow-up off therapy an additional 16 weeks. Fifty-nine patients compensated hepatitis were entered. Efficacy was measured at the end and after by normalization alanine aminotransferase (ALT), improvement in histology, reduction virus (HCV) RNA level symptoms. Among recipients, 12 29...
Hepatitis C infects nearly 4 million Americans. Most have chronic hepatitis (CHC), which progresses to cirrhosis in about 20% of patients. Interferon treatment leads transient responses 40% patients and apparent eradication infection 7% In this report, we document the impact CHC on health-related quality life (HQL), changes HQL among responders. Three hundred twenty-four from 10 countries who had relapsed after responding interferon-alfa therapy were randomized monotherapy (IFN alfa-2b +...
Cellular immune responses, particularly those mediated by CD8+ CTL, may be important in the pathogenesis and control of hepatitis C virus (HCV) infection. To define role HCV-specific CTL chronic C, activity liver peripheral blood was assessed 35 patients with HCV infection 5 non-HCV controls. expanded cells evaluated against autologous lymphoblastoid transduced recombinant vaccinia vectors expressing genotype 1a Ags. detected unprimed bulk-expanded derived from 16 patients, but not...
Nonalcoholic steatohepatitis (NASH) may account for many cases of cryptogenic cirrhosis. If so, then steatosis might recur after liver transplantation. Two thousand fifty-two patients underwent primary transplantation chronic disease between 1986 and 2004. Serial biopsy samples were assessed fibrosis. hundred fifty-seven (12%) had a pretransplant diagnosis cirrhosis (239) or NASH (18). Fatty developed in 31% was more common when the (45% at 5 years versus 23% cirrhosis, P = 0.007). only 4%...
Journal Article Application of Six Hepatitis C Virus Genotyping Systems to Sera from Chronic Patients in the United States Get access Johnson Y. N. Lau, Lau Reprints or correspondence: Dr. Section Hepatobi1iary Diseases, Dept. Medicine, University Florida, P.O. Box 100214 JHMHC, Gainesville, FL 32610. Search for other works by this author on: Oxford Academic PubMed Google Scholar Masashi Mizokami, Mizokami Janice A. Kolberg, Kolberg Gary L. Davis, Davis Linda E. Prescott, Prescott Tomoyoshi...
Abstract Brain metastases of breast cancer seem to be increasingin incidence as systemic therapy improves. Metastatic disease in the brain is associated with high morbidity and mortality. We present first gene expression analysis laser-captured epithelial cells from resected human compared unlinked primary tumors. The tumors were matched for histology, tumor-node-metastasis stage, hormone receptor status. Most differentially expressed genes down-regulated metastases, which included,...
AbstractHepatocellular carcinoma (HCC) is a common cancer that typically occurs in the setting of cirrhosis and chronic hepatitis virus infections. Hepatitis B C account for approximately 80% cases worldwide. HCC currently fifth most malignancy men eighth women worldwide; its incidence increasing dramatically many parts world. Recognition those at risk early diagnosis by surveillance with imaging, or without serologic testing, are extremely important. Many highly effective even curative...
Hepatocellular carcinoma (HCC) is a common indication for liver transplantation (LT). Currently, deceased donor LT approved by the United Network Organ Sharing patients with HCC who meet Milan criteria of single tumor up to 5 cm or 3 tumors as determined imaging studies. We analyzed data in International Registry Hepatic Tumors Liver Transplantation from 1,206 HCC. Tumor size and number were gross pathologic examination. Kaplan-Meier recurrence-free survival ≤5 2-3 lesions all ≤3 diameter...
Pulmonary hypertension in the setting of cirrhosis and portal is known as portopulmonary (PPHTN). Moderate or severe PPHTN uncommon, but has a poor prognosis considered to be contraindication liver transplantation. We assessed impact vasodilation therapy on pulmonary hemodynamics outcome after transplant these patients. Eighty-six patients evaluated for between 1997 2005 had an estimated right ventricular systolic pressure >40 mm Hg clinical suspicion PPHTN. Right heart catheterization...